Codexis will make its annual splash at the TIDES USA conference May 11-14, which is the leading conference for oligonucleotide nerdery. Oligonucleotides ("oligos" for shot) are things like RNA. The industrial enzyme manufacturer will share updates on ligation services (an important stepping stone to full ECO Synthesis), controlling stereopurity of oligos (potentially yielding lower doses of less-frequently administered RNAi), and the sustainability of enzymatic synthesis. It'll also host a talk with former Alnylam Pharma CEO and founder John Maraganore, Arrowhead Pharma's head of CMC, and Codexis CEO Alison Moore.

As for the attractiveness of shares, Codexis does need to raise more capital to pursue its vision. It also needs more concrete signs of buy-in from RNAi drug developers. One problem for investors: by the time that press release comes across your screen, it might be "too late" to start a position. I'm interested in Codexis as one of my core long-term positions, but am happy to seed it in 2026 before potentially building a larger position in late 2026 or 1H 2027.